Latest Insider Transactions at Vertex Pharmaceuticals Inc (VRTX)
This section provides a real-time view of insider transactions for Vertex Pharmaceuticals Inc (VRTX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of VERTEX PHARMACEUTICALS INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of VERTEX PHARMACEUTICALS INC 's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 09
2023
|
Sangeeta N. Bhatia Director |
SELL
Open market or private sale
|
Direct |
242
-5.23%
|
$83,490
$345.51 P/Share
|
|
Aug 09
2023
|
David Altshuler EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
63
-0.2%
|
$21,735
$345.51 P/Share
|
|
Jul 17
2023
|
Bruce I Sachs Director |
SELL
Open market or private sale
|
Direct |
11,250
-7.87%
|
$4,005,000
$356.53 P/Share
|
|
Jul 17
2023
|
Bruce I Sachs Director |
BUY
Exercise of conversion of derivative security
|
Direct |
11,250
+18.0%
|
$1,428,750
$127.54 P/Share
|
|
Jul 17
2023
|
Reshma Kewalramani CEO & President |
SELL
Open market or private sale
|
Direct |
7,828
-6.18%
|
$2,778,940
$355.0 P/Share
|
|
Jun 15
2023
|
Stuart A Arbuckle EVP, COO |
SELL
Open market or private sale
|
Direct |
8,603
-13.2%
|
$3,002,447
$349.0 P/Share
|
|
Jun 15
2023
|
Stuart A Arbuckle EVP, COO |
BUY
Exercise of conversion of derivative security
|
Direct |
8,603
+11.66%
|
$1,608,761
$187.53 P/Share
|
|
May 30
2023
|
Stuart A Arbuckle EVP, COO |
SELL
Open market or private sale
|
Direct |
82
-0.14%
|
$26,978
$329.82 P/Share
|
|
May 30
2023
|
Kristen Ambrose SVP & Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
289
-4.06%
|
$95,081
$329.82 P/Share
|
|
May 08
2023
|
Bastiano Sanna EVP, Cell & Genetic Therapies |
SELL
Open market or private sale
|
Direct |
2,850
-8.17%
|
$997,500
$350.0 P/Share
|
|
May 08
2023
|
Jeffrey M Leiden Executive Chairman |
SELL
Open market or private sale
|
Direct |
1,125
-3.08%
|
$392,625
$349.0 P/Share
|
|
May 05
2023
|
Bastiano Sanna EVP, Cell & Genetic Therapies |
SELL
Open market or private sale
|
Direct |
422
-1.2%
|
$147,700
$350.03 P/Share
|
|
May 05
2023
|
Jeffrey M Leiden Executive Chairman |
SELL
Open market or private sale
|
Direct |
879
-1.18%
|
$306,771
$349.84 P/Share
|
|
May 03
2023
|
Bastiano Sanna EVP, Cell & Genetic Therapies |
SELL
Open market or private sale
|
Direct |
2,781
-3.7%
|
$976,131
$351.02 P/Share
|
|
May 03
2023
|
Jeffrey M Leiden Executive Chairman |
SELL
Open market or private sale
|
Direct |
4,508
-3.71%
|
$1,577,800
$350.45 P/Share
|
|
May 02
2023
|
Bastiano Sanna EVP, Cell & Genetic Therapies |
SELL
Open market or private sale
|
Direct |
1,622
-1.37%
|
$569,322
$351.74 P/Share
|
|
May 02
2023
|
Jeffrey M Leiden Executive Chairman |
SELL
Open market or private sale
|
Direct |
6,450
-4.59%
|
$2,263,950
$351.05 P/Share
|
|
May 02
2023
|
Sangeeta N. Bhatia Director |
SELL
Open market or private sale
|
Direct |
580
-2.33%
|
$201,840
$348.36 P/Share
|
|
May 01
2023
|
Suketu Upadhyay Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,168
+29.99%
|
-
|
|
May 01
2023
|
Diana Mckenzie Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,168
+30.97%
|
-
|
|
May 01
2023
|
Diana Mckenzie Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,449
-50.24%
|
-
|
|
May 01
2023
|
Alan M Garber Director |
BUY
Grant, award, or other acquisition
|
Direct |
584
+8.27%
|
-
|
|
May 01
2023
|
Sangeeta N. Bhatia Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,168
+18.32%
|
-
|
|
May 01
2023
|
Lloyd Carney Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,168
+18.01%
|
-
|
|
Apr 27
2023
|
Reshma Kewalramani CEO & President |
SELL
Open market or private sale
|
Direct |
3,317
-0.86%
|
$1,124,463
$339.44 P/Share
|
|
Apr 13
2023
|
Bruce I Sachs Director |
SELL
Bona fide gift
|
Direct |
1,210
-2.94%
|
-
|
|
Apr 12
2023
|
Bastiano Sanna EVP, Cell & Genetic Therapies |
SELL
Open market or private sale
|
Direct |
7,567
-5.6%
|
$2,466,842
$326.53 P/Share
|
|
Apr 12
2023
|
Bruce I Sachs Director |
SELL
Open market or private sale
|
Direct |
21,300
-12.78%
|
$6,943,800
$326.53 P/Share
|
|
Apr 12
2023
|
Bruce I Sachs Director |
BUY
Exercise of conversion of derivative security
|
Direct |
21,300
+25.41%
|
$1,533,600
$72.14 P/Share
|
|
Apr 04
2023
|
Bastiano Sanna EVP, Cell & Genetic Therapies |
SELL
Open market or private sale
|
Direct |
522
-0.22%
|
$164,952
$316.59 P/Share
|
|
Mar 31
2023
|
Kristen Ambrose SVP & Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
176
-2.41%
|
$55,088
$313.74 P/Share
|
|
Mar 31
2023
|
Bastiano Sanna EVP, Cell & Genetic Therapies |
SELL
Payment of exercise price or tax liability
|
Direct |
1,466
-2.98%
|
$458,858
$313.74 P/Share
|
|
Mar 24
2023
|
Charles F Wagner Jr EVP & Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,768
-3.44%
|
$539,240
$305.38 P/Share
|
|
Mar 17
2023
|
Charles F Wagner Jr EVP & Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,000
-0.63%
|
$594,000
$297.51 P/Share
|
|
Mar 16
2023
|
Bastiano Sanna EVP, Cell & Genetic Therapies |
SELL
Open market or private sale
|
Direct |
2,746
-2.65%
|
$823,800
$300.81 P/Share
|
|
Mar 13
2023
|
Charles F Wagner Jr EVP & Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,666
-0.81%
|
$781,138
$293.54 P/Share
|
|
Mar 10
2023
|
Charles F Wagner Jr EVP & Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,088
-0.46%
|
$605,520
$290.69 P/Share
|
|
Feb 27
2023
|
Ourania Tatsis EVP, Chief Reg. & Quality Off. |
SELL
Open market or private sale
|
Direct |
354
-0.21%
|
$101,952
$288.27 P/Share
|
|
Feb 27
2023
|
Kristen Ambrose SVP & Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
1,207
-4.85%
|
$347,616
$288.52 P/Share
|
|
Feb 27
2023
|
Stuart A Arbuckle EVP, COO |
SELL
Open market or private sale
|
Direct |
5,034
-2.77%
|
$1,444,758
$287.89 P/Share
|
|
Feb 27
2023
|
David Altshuler EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
4,238
-3.96%
|
$1,220,544
$288.52 P/Share
|
|
Feb 24
2023
|
Ourania Tatsis EVP, Chief Reg. & Quality Off. |
SELL
Payment of exercise price or tax liability
|
Direct |
3,308
-5.47%
|
$956,012
$289.12 P/Share
|
|
Feb 24
2023
|
Charles F Wagner Jr EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,308
-5.38%
|
$956,012
$289.12 P/Share
|
|
Feb 24
2023
|
Bastiano Sanna EVP, Cell & Genetic Therapies |
SELL
Payment of exercise price or tax liability
|
Direct |
3,970
-7.09%
|
$1,147,330
$289.12 P/Share
|
|
Feb 24
2023
|
Jeffrey M Leiden Executive Chairman |
SELL
Payment of exercise price or tax liability
|
Direct |
13,730
-22.12%
|
$3,967,970
$289.12 P/Share
|
|
Feb 24
2023
|
Amit Sachdev EVP Chief Patient & Ext Af Off |
SELL
Payment of exercise price or tax liability
|
Direct |
2,468
-3.58%
|
$713,252
$289.12 P/Share
|
|
Feb 24
2023
|
Carmen Bozic EVP and CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,308
-4.97%
|
$956,012
$289.12 P/Share
|
|
Feb 24
2023
|
Reshma Kewalramani CEO & President |
SELL
Payment of exercise price or tax liability
|
Direct |
9,386
-6.74%
|
$2,712,554
$289.12 P/Share
|
|
Feb 24
2023
|
Kristen Ambrose SVP & Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
502
-5.57%
|
$145,078
$289.12 P/Share
|
|
Feb 24
2023
|
Stuart A Arbuckle EVP, COO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,714
-7.11%
|
$1,362,346
$289.12 P/Share
|